Navigation Links
Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
Date:5/24/2013

WELWYN GARDEN CITY, England and BOSTON, May 24, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akira Usui as a Consultant to augment the Company's business development capabilities in Japan and other Asian territories.

Mr Usui has more than 15 years of experience in business development, licensing and alliance management in the pharmaceutical industry including senior roles at Perlegen Sciences, Inc., Roche Pharma (Japan), Nippon Roche and Tanabe Seiyaku Co. Ltd. Mr Usui is President of Ray Life Sciences Inc., which he established in 2007 to provide business and corporate development consulting services to pharma and biotech companies, universities and venture capital firms with a specific focus on the Japanese market.

Barry Kenny , Heptares' Chief Business Officer, said: "Akira has an exceptional depth of experience in business development and an impressive track record in implementing agreements across multiple international territories. In addition to our existing partnership with Takeda, we are developing significant interest from pharmaceutical companies in Japan in what Heptares' technology can offer. We look forward to working with Akira, who will provide additional support in this region, to manage and advance these multiple new business opportunities for our unique GPCR-focused drug discovery and development capabilities."  

Mr Usui added: "Heptares has established itself as the leader in GPCR-focused drug discovery and has achieved significant milestones both with its partners and in building its own pipeline of drug candidates. Its platform and approach has the potential to unlock the GPCR space to drug discovery and enable the development of new and better targeted medicines for diseases with few effective treatments. I am delighted to work with the Company as it seeks to increase its business development activities in Japan and Asia."

 

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares and UK Medical Research Council Extend GPCR Collaboration
2. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
3. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
4. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
5. Generex Augments Antigen Express Scientific Advisory Board
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
9. Nominations Open for San Francisco Business Times Health Care Heroes Awards
10. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
11. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global lifestyle drugs market to grow at a CAGR of ... Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... Calif. , March 29, 2017 Varian Medical ... will report results for the second quarter of fiscal year ... 26, 2017.  The news release will be followed by a ... The news release and a link to the conference call ... www.varian.com/investor .  To access the teleconference call and replay: ...
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... The ... offerings of corporate finance programs to address the increasingly complex educational needs of ... increase their knowledge of sophisticated corporate finance and will increase their ability to ...
(Date:3/30/2017)... ... ... An inventor and manicurist from Greet, S.C., wants to offer people a new way to ... clean and healthy feet, so I know the importance of proper foot care," he said. ... the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in ... Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, ... discusses strategies to prevent readmissions in light of the most recent programs at ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
Breaking Medicine News(10 mins):